Century Therapeutics, Inc. Sale of Stock, Consideration Received on Transaction
Century Therapeutics, Inc. (IPSC) had Sale of Stock, Consideration Received on Transaction of $126.70 million as of 2026-01-09, per its 10-K filed 2026-03-12.
Financial Statements › Notes
us-gaap:SaleOfStockConsiderationReceivedOnTransaction · last filed 2026-03-12
- 2026-01-09: Sale of Stock, Consideration Received on Transaction $126.70M.
| Period end | Sale of Stock, Consideration Received on Transaction |
|---|---|
| 2026-01-09 | $126.70M 10-K · filed 2026-03-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |